Morphosys AG (GB:0NDV) has disclosed a new risk, in the Share Price & Shareholder Rights category.
In the event that MorphoSys AG’s ordinary shares remain post-Novartis takeover offer, a significant decrease in liquidity and market value is anticipated. The reduced free float could lead to difficulties for minority shareholders in selling their shares and potentially result in their exclusion from German SDAX & TecDAX stock indices, causing further adverse effects on share price due to potential index fund sell-offs. Similarly, the American Depositary Shares (ADSs) listed on Nasdaq may suffer from reduced liquidity, increased volatility, and the risk of trading suspension or delisting, compounding the risk for investors holding these securities.
Overall, Wall Street has a Hold consensus rating on GB:0NDV stock based on 1 Buy and 6 Holds.
To learn more about Morphosys AG’s risk factors, click here.
